CGC Genomics has announced the close of its €1.7 million pre-seed funding round to accelerate development of Qnomx, its GenAI-powered platform for regulatory-compliant cancer genomics interpretation. The round includes investment from Heal Capital, Labor Becker MVZ eGbR, better ventures, Superangels, Springboard Health Angels, JVH Ventures, and several individual backers.
Qnomx enables clinical laboratories to automate the manual review of complex genomic profiles, a key bottleneck in oncology diagnostics. By improving the speed and accuracy of cancer genomic data interpretation, CGC Genomics aims to reduce costs and streamline testing workflows. The company said the platform enhances decision-making and accelerates treatment timelines, ultimately helping physicians make faster, more informed therapy selections.
Featured image: Credit: CGC Genomics
